Welcome to our dedicated page for BlackRock Science and Tech Term ord SEC filings (Ticker: BSTZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BlackRock Science and Technology Term Trust (BSTZ) SEC filings page on Stock Titan is intended to help investors review the regulatory documents and related information that describe how this closed-end fund operates. While no specific filings are listed in the provided data, BlackRock notes that annual and semi-annual reports and other regulatory filings for its funds are accessible on the U.S. Securities and Exchange Commission’s website, and that these documents may discuss factors affecting the fund.
As a non-diversified, closed-end management investment company focused on science and technology-related securities, BSTZ’s filings typically explain its investment objectives, which are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. They also describe the types of securities the fund may hold, including equity securities, options, preferred securities, convertible securities, depositary receipts, non-U.S. securities, emerging markets investments, restricted and illiquid investments, private company investments, corporate bonds, and other investments.
Regulatory reports and related disclosures also outline distribution policies. BlackRock has publicly discussed BSTZ’s managed distribution plan, under which the fund distributes all available investment income consistent with its objectives and tax requirements. If sufficient income and short-term gains are not available, the fund may distribute long-term capital gains and/or return of capital to maintain a level distribution. Estimates of the sources of distributions, such as net income, net realized gains, and return of capital, are provided in regulatory notices and press releases.
On Stock Titan, AI-powered tools can help interpret information from BSTZ’s filings and related disclosures by summarizing key points about its investment strategy, distribution framework, and capital management actions such as tender offers. This allows investors to more quickly understand the implications of lengthy documents while still relying on the underlying reports available through official channels.
BlackRock Science and Technology Term Trust (BSTZ) delivered its certified shareholder report for the fiscal period ending
The report discloses the Trust’s current monthly distribution of $0.162500 and an annualized distribution of $1.950000, showing a stated distribution rate of 8.62% on the closing market price of $22.61 as of
BlackRock Science & Technology Term Trust vice president Stephen Thomas Minar reported buying additional common shares of BSTZ. On February 10, 2026, he made several open‑market purchases at prices around $23.15 per share, including trades at $23.08 and $23.14.
After these transactions, Minar directly owned 8,074.209 shares of the trust’s common stock, indicating increased personal exposure to the fund.
BlackRock Science & Technology Term Trust portfolio manager Tony Kim reported buying additional common shares of BSTZ. On February 5, 2026, he purchased 41,525 shares at $22 per share and 300 shares at $21.96 per share. The filing shows directly owned positions of 251,554.3651 and 210,029.3651 common shares following the respective transactions.
BlackRock Science & Technology Term Trust (BSTZ) portfolio manager Tony Kim reported a mix of phantom share awards, conversions and a stock sale. On January 30, 2026, he received 20,534.0483 phantom shares, each economically equivalent to one common share and payable in cash as they vest over three years.
On the same date, 9,845.5493 and 5,734.6195 phantom shares were converted into the same number of common shares. Kim then sold 15,580.1688 common shares at $22.38 per share, leaving him with 208,712 common shares held directly after the sale.
Saba Capital Management and related reporting persons disclose a significant position in BlackRock Science & Technology Term Trust common shares. They report beneficial ownership of 4,682,590 common shares, representing 6.81% of the class, based on 68,744,150 shares outstanding as of 6/30/25. The shares are held with shared voting and dispositive power among Saba Capital, Saba Capital Management GP, LLC, and Boaz R. Weinstein.
Approximately $80,499,717 was paid to acquire these shares, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. The funds and accounts advised by Saba Capital are entitled to receive dividends and any sale proceeds from these shares. Recent transactions in the stock over the sixty days before 1/14/26 are detailed in an attached Schedule A.
BlackRock Science & Technology Term Trust reported an insider stock sale by one of its directors. The reporting person sold 9,293 shares of common stock on 12/18/2025 at a price of $22.51 per share. On 12/19/2025, the same person reported an additional sale of 0.6469 shares at $22.73 per share. After these transactions, the filing shows the director beneficially owning 0 shares of the trust’s common stock in direct ownership.